Health Care & Life Sciences » Pharmaceuticals | Bio-Path Holdings Inc.

Bio-Path Holdings Inc. | Ownership

Companies that own Bio-Path Holdings Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
University of Texas Investment Management Co.
383,089
3.38%
1
0.19%
06/30/2018
Renaissance Technologies LLC
198,730
1.75%
62,000
0%
06/30/2018
The Vanguard Group, Inc.
142,914
1.26%
-87,760
0%
06/30/2018
G1 Execution Services LLC
90,060
0.79%
90,060
0.01%
06/30/2018
Geode Capital Management LLC
52,458
0.46%
0
0%
06/30/2018
Commonwealth Equity Services, Inc.
44,008
0.39%
-378
0%
06/30/2018
Securities America Advisors, Inc.
20,514
0.18%
0
0%
06/30/2018
Northern Trust Investments, Inc.
17,687
0.16%
-11,040
0%
06/30/2018
HighTower Advisors LLC
17,000
0.15%
0
0%
06/30/2018
Raymond James Financial Services Advisors, Inc.
14,928
0.13%
0
0%
06/30/2018

About Bio-Path Holdings

View Profile
Address
4710 Bellaire Boulevard
Bellaire Texas 77401
United States
Employees -
Website http://www.biopathholdings.com
Updated 07/08/2019
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P.